Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccine R&D Tax Credit Proposal Supported By Findings In CRS Report

Executive Summary

A 30% tax credit on vaccine R&D could be as cost- effective as direct federal investment in vaccine development through government grants, a Congressional Research Service report states.

You may also be interested in...



Vaccine Tax Credit In Clinton Budget Is Based On Sales To Nonprofit Groups

President Clinton's tax credit to encourage the development of vaccines for targeted diseases would be based on sales to nonprofit organizations rather than the amount spent on research and development.

Vaccine Tax Credit In Clinton Budget Is Based On Sales To Nonprofit Groups

President Clinton's tax credit to encourage the development of vaccines for targeted diseases would be based on sales to nonprofit organizations rather than the amount spent on research and development.

Clinton Emphasizes Biomedical Research Over Rx Cost In State Of The Union

President Clinton's State of the Union message emphasized the value of biomedical research rather than the cost of drugs.

Related Content

UsernamePublicRestriction

Register

PS035022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel